Life Sciences M&A Advisory

Strategic Transactions
in Life Sciences

Cresca Capital is a specialized advisory firm guiding biotech companies through transformative mergers, acquisitions, and strategic financings.

Get in Touch
Therapeutic Focus

Where We Specialize

Cresca Capital concentrates its advisory practice across high-impact therapeutic categories at the forefront of biomedical innovation.

Neuro / CNS

Pain

Hearing

Women's Health

Metabolic Disorders

Longevity

Advisory Services

What We Do

We provide end-to-end transaction advisory across buy-side and sell-side mandates, with deep expertise in life sciences deal structuring.

Buy-Side Sell-Side

Search & Evaluation

Systematic identification and prioritization of targets or acquirers aligned with strategic objectives. We map the competitive landscape and surface the right counterparties before opportunities reach the open market.

Buy-Side Sell-Side

Due Diligence

Comprehensive scientific, commercial, and financial diligence — whether assessing a target's pipeline and IP or preparing a seller's data room to withstand rigorous buyer scrutiny.

Buy-Side Sell-Side

Transaction Execution

End-to-end process management from term sheet through closing — including valuation, negotiation strategy, deal structuring, and coordination with legal, regulatory, and financial counterparties.

Buy-Side Sell-Side

Special Situations

Advisory on complex or time-sensitive transactions — asset carve-outs, licensing partnerships, spin-outs, royalty monetizations, and restructurings requiring creative structuring and rapid execution.

Sell-Side

Pre-IPO Preparation

Strategic and structural readiness advisory for companies approaching a public offering — including equity story development, investor positioning, and coordination with underwriters and counsel ahead of listing.

Team

Registered Representative

HT
Registered Representative

Heloise Taillet

BA Economics-Mathematics  ·  Columbia College, Columbia University

Heloise advises on M&A and fundraising as a Registered Representative with Cresca Capital, a life sciences-focused advisory firm (neuro/CNS, pain, women's health, and longevity), and as a Partner at Luminarc Labs, where she works with investors and startups on high-impact projects.

Prior to these roles, she sourced and diligenced acquisition and investment opportunities at Saltwater Capital (founded by Uber's first CEO, Ryan Graves), Thrasio (ecommerce unicorn), and Secocha Ventures (early-stage VC).

Heloise holds a Bachelor's degree in Economics-Mathematics from Columbia College, Columbia University.

Contact

Get in Touch

We welcome inquiries from founders, management teams, and investors navigating transactions in the life sciences sector.

heloise@crescacap.com

Response within one business day

Whether you're exploring a potential acquisition, preparing for a sale process, or evaluating strategic alternatives, Cresca Capital can provide the expertise and relationships to help you execute with confidence.

Securities are offered through Finalis Securities LLC Member FINRA / SIPC. Cresca Capital is not a registered broker-dealer, and Finalis Securities LLC and Cresca Capital are separate, unaffiliated entities. Finalis Securities LLC, Office of Supervisory Jurisdiction is located at 450 Lexington Ave, New York, NY 10017, 800-962-0418.

Finalis Privacy Policy  |  Finalis Business Continuity Plan  |  FINRA BrokerCheck  |  Finalis Form Customer Relationship Summary ("Form CRS")

crescacap.com (the “Cresca Capital Website”) is a website operated by Cresca Capital. This website is for informational purposes only, is not an offer, solicitation, recommendation, or commitment for any transaction or to buy or sell any security or other financial product, and is not intended as investment advice or as a confirmation of any transaction. Products and services on this website may not be available for residents of certain jurisdictions. Please consult with a Finalis Securities’ registered representative regarding the product or service in question for further information. Investments involve risk and are not guaranteed to appreciate. Any market price, indicative value, estimate, view, opinion, data, or other information herein is not warranted as to completeness or accuracy, is subject to change without notice, and Cresca Capital along with Finalis Securities LLC accepts no liability for its use or to update it or keep it current.

Investing in private placements involves a high degree of risk. These investments may be illiquid, speculative, and subject to substantial restrictions on transferability. Investors may lose all or part of their investment and should only invest capital they can afford to lose. Prospective investors should conduct their own due diligence and consult with their legal, tax, and financial advisors prior to making any investment decision. For your reference, Finalis’ Form CRS describes the services that we provide, how we are compensated, and other important information about Finalis Securities LLC.